Cas no 129-20-4 (Oxyphenbutazone)

Oxyphenbutazone is a nonsteroidal anti-inflammatory drug (NSAID) derived from phenylbutazone, primarily used for its analgesic, anti-inflammatory, and antipyretic properties. It functions by inhibiting cyclooxygenase (COX) enzymes, thereby reducing prostaglandin synthesis. Oxyphenbutazone is particularly effective in managing pain and inflammation associated with musculoskeletal conditions, such as arthritis and gout. Its key advantages include a longer half-life compared to some NSAIDs, allowing for less frequent dosing, and its ability to provide sustained relief from chronic inflammatory conditions. However, due to potential adverse effects, including gastrointestinal and hematological risks, its use is now limited in many regions. Proper medical supervision is advised when administering this compound.
Oxyphenbutazone structure
Oxyphenbutazone structure
Product Name:Oxyphenbutazone
CAS No:129-20-4
MF:C19H20N2O3
MW:324.373704910278
CID:143046
PubChem ID:4641
Update Time:2025-10-25

Oxyphenbutazone Chemical and Physical Properties

Names and Identifiers

    • 3,5-Pyrazolidinedione,4-butyl-1-(4-hydroxyphenyl)-2-phenyl-
    • OXYPHENYL BUTAZONE
    • 4-butyl-1-(4-hydroxyphenyl)-2-phenylpyrazolidine-3,5-dione
    • Oxyphenbutazone
    • 4-Butyl-1-(4-hydroxyphenyl)-2-phenyl-3,5-pyrazolidinedione G 27202
    • Etrozolidina
    • Idrobutazina
    • ossifenbutazone
    • Oxazolidin
    • Oxi-Fenibutol
    • Oxifenylbutazon
    • Oxiphenbutazone
    • oxyphenbutazon
    • p-Oxyphenylbutazone
    • Tanderil
    • 4-Butyl-1-(4-hydroxyphenyl)-2-phenyl-3,5-pyrazolidinedione
    • G 27202
    • NSC 526053
    • Ro 04-4410
    • p-Hydroxyphenylbutazone
    • 4-Butyl-2-(p-hydroxyphenyl)-1-phenyl-3,5-pyrazolidinedione
    • Butapirone
    • Californit
    • Crovaril
    • Flamaril
    • Floghene
    • Flogitolo
    • Flogoril
    • Frabel
    • Metabolite I
    • Neo-Farmadol
    • Offitril
    • Oxalid
    • Oxyphenobutazone
    • Rapostan
    • Romaxin
    • Suganril
    • Tandacote
    • Tandearil
    • Telidal
    • Tendearil
    • Visubutina
    • bm1
    • Flogal
    • Iridil
    • Mysite
    • Neofen
    • Reumox
    • c
    • Oxyphenylbutazone
    • BM 1
    • g27202
    • MS-24837
    • D08324
    • Prestwick3_001049
    • SBI-0051471.P003
    • Artroflog
    • Flegmostam
    • Tox21_110414_1
    • AKOS024362800
    • Spectrum_001073
    • Butilene
    • M01AA03
    • KBio1_000302
    • J-005659
    • G-29701
    • Remazin
    • HMS2098A20
    • Oxyphenbutazonum
    • 1-(p-Hydroxyphenyl)-2-phenyl-3,5-dioxo-4-N-butylpyrazolidine
    • BDBM200298
    • Aradinum
    • 1-p-Hydroxyphenyl-2-phenyl-3,5-dioxo-4-N-butylpyrazolidine
    • Hydroxyphenylbutazone
    • DivK1c_000302
    • HMS500P04
    • FT-0673468
    • C19494
    • 129-20-4
    • 1-(p-hydroxyphenyl)-2-phenyl-4-butylpyrazolidine-3,5-dione
    • Optimal
    • AI3-26792
    • Reozon (TN)
    • 1-Phenyl-2-(p-hydroxyphenyl)-3,5-dioxo-4-butylpyrazolidine
    • Oxyphenbutazone [INN]
    • KBioSS_001553
    • 3,5-Pyrazolidinedione, 4-butyl-1-(p-hydroxyphenyl)-2-phenyl-(VAN)
    • Spectrum2_000153
    • 1-Phenyl-2-(p-hydroxyphenyl)-3,5-dioxo-4-n-butylpyrazolidine
    • DB03585
    • NSC757261
    • Oxifenbutazona [INN-Spanish]
    • 4-Butyl-2-(4-hydroxyphenyl)-1-phenyl-3,5-dioxopyrazolidine
    • OXYPHENBUTAZONE [WHO-DD]
    • EN300-761427
    • Reozon
    • BSPBio_000978
    • Piraflogin
    • HMS3715A20
    • SR-05000001689-1
    • OXYPHENBUTAZONE (IARC)
    • DTXSID1045291
    • KBio2_006689
    • Oxyphenbutazone 1000 microg/mL in Acetonitrile
    • Isobutil
    • Pirabutina
    • 3, 4-butyl-1-(4-hydroxyphenyl)-2-phenyl-
    • Portoril
    • UNII-A7D84513GV
    • Usaf Ge-14
    • SPBio_002909
    • Flogodin
    • Oxifenbutazona
    • S01BC02
    • BPBio1_001076
    • Cinophen-N
    • Hydroxyphenylbutazon
    • (+/-)-OXYPHENBUTAZONE ANHYDROUS
    • CS-0013099
    • NSC-757261
    • Tanderal
    • metabolitie
    • Poliflogil
    • Tox21_110414
    • Deflogin
    • Butaflogin
    • SPECTRUM1500455
    • DTXCID9025291
    • Isobutazina
    • 4-Butyl-1-(p-hydroxyphenyl)-2-phenyl-3,5-pyrazolidinedione
    • CHEBI:76258
    • (+/-)-OXYPHENBUTAZONE MONOHYDRATE
    • Prestwick1_001049
    • Flogostop
    • KBio2_001553
    • HMS1571A20
    • KBioGR_001729
    • 3,5-Pyrazolidinedione, 4-butyl-1-(p-hydroxyphenyl)-2-phenyl-
    • HMS2236G07
    • OXYPHENBUTAZONE ANHYDROUS, (+/-)-
    • HMS2091L20
    • CHEMBL1228
    • 4-butyl-1-(4-hydroxyphenyl)-2-phenyl-pyrazolidine-3,5-dione
    • Reunabutal
    • Pharmakon1600-01500455
    • Butanova
    • SR-05000001689-3
    • HMS1920D20
    • Prestwick2_001049
    • Oxazolidin-Geigy
    • WLN: T5VNNV EHJ BR DQ & CR & E4
    • F82061
    • Oxyphentamin
    • Telidac
    • SCHEMBL25857
    • SPBio_000286
    • IDI1_000302
    • OPB
    • CCG-38944
    • BSPBio_002149
    • CAS-129-20-4
    • AB00052064_08
    • SR-05000001689
    • Oxyphenbutazone (TN)
    • Oxazolioin
    • MLS003373849
    • M02AA04
    • 3,5-Pyrazolidinedione, 4-butyl-1-(4-hydroxyphenyl)-2-phenyl
    • Prestwick0_001049
    • BRN 0307474
    • oxifenbutazone
    • 3, 4-butyl-1-(p-hydroxyphenyl)-2-phenyl-
    • Oxiphenbutazonum
    • HMS3373B01
    • Spectrum5_000998
    • Butazonic
    • NCGC00094748-07
    • 3,5-Pyrazolidinedione, 4-butyl-1-(4-hydroxyphenyl)-2-phenyl-
    • Flogistin
    • Oxyphenbutazone (INN)
    • Rumapax
    • Oxybuton
    • EINECS 204-936-2
    • BRD-A33749298-001-05-0
    • NCGC00094748-03
    • A7D84513GV
    • NCGC00016389-01
    • Infamil
    • 3,5-Pyrazolidinedione, 4-butyl-1-(p-hydroxyphenyl)-2-phenyl- (VAN)
    • Flopirina
    • G-27202
    • Oxyphenbutazone anhydrous
    • CCRIS 6717
    • KBio3_001649
    • NS00009020
    • 3,5-Dioxo-1-phenyl-2-(p-hydroxyphenyl)-4-N-butylpyrazolidene
    • OXYPHENBUTAZONE MONOHYDRATE, (+/-)-
    • Q4116192
    • RO-04-4410
    • NCGC00094748-04
    • Spectrum3_000535
    • NSC526053
    • OXYPHENBUTAZONE [MI]
    • Oxyphenbutazone, Tanderil
    • AB00052064
    • NSC-526053
    • Flanaril
    • 1-(p-Hydroxyphenyl)-2-phenyl-4-butyl-3,5-pyrazolidinedione
    • KBio2_004121
    • NINDS_000302
    • BCP20014
    • NCGC00094748-01
    • Oxyphenbutazonum (INN-Latin)
    • Ipabutona
    • Genal
    • Oxifenbutazona (INN-Spanish)
    • OXYPHENBUTAZONE 4-HYDROXYPHENYLBUTAZONE
    • Oxibutol
    • Decanoylm-nitroaniline
    • HY-B1355A
    • Valioil
    • Infammil
    • Butanora
    • HSDB 3144
    • Ossifenbutazone [DCIT]
    • NCGC00094748-02
    • Tandalgesic
    • OXYPHENBUTAZONE [HSDB]
    • Spectrum4_001155
    • (+/-)-Oxyphenbutazone-d9(N-butyl-d9)
    • Oxyphenbutazonum [INN-Latin]
    • GLXC-03195
    • BRD-A33749298-001-18-3
    • DA-63652
    • MDL： MFCD00057278
    • Inchi： 1S/C19H20N2O3/c1-2-3-9-17-18(23)20(14-7-5-4-6-8-14)21(19(17)24)15-10-12-16(22)13-11-15/h4-8,10-13,17,22H,2-3,9H2,1H3
    • InChI Key： HFHZKZSRXITVMK-UHFFFAOYSA-N
    • SMILES： O=C1C(C(N(C2C=CC=CC=2)N1C1C=CC(=CC=1)O)=O)CCCC

Computed Properties

  • Exact Mass: 324.14700
  • Monoisotopic Mass: 324.14739250g/mol
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 1
  • Hydrogen Bond Acceptor Count: 3
  • Heavy Atom Count: 24
  • Rotatable Bond Count: 5
  • Complexity: 454
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 0
  • Undefined Atom Stereocenter Count : 1
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • Surface Charge: 0
  • Tautomer Count: 6
  • XLogP3: nothing
  • Topological Polar Surface Area: 60.8?2

Experimental Properties

  • Density: 1.241±0.06 g/cm3 (20 oC 760 Torr),
  • Melting Point: 124-125 oC
  • Boiling Point: 462.71°C (rough estimate)
  • Flash Point: 247.5±29.3 °C
  • Refractive Index: 1.6140 (estimate)
  • Solubility: Almost insoluble (0.071 g/l) (25 o C),
  • PSA: 60.85000
  • LogP: 3.62340
  • Solubility: Soluble in ethanol \ acetone, chloroform \ benzene \ ether, insoluble in water. Soluble in carbon hydroxide or alkali carbonate solution
  • Vapor Pressure: 0.0±1.3 mmHg at 25°C

Oxyphenbutazone Security Information

  • Symbol: GHS07 GHS09
  • Signal Word：Warning
  • Hazard Statement： H302-H400
  • Warning Statement： P273
  • Hazardous Material transportation number：UN 3077 9 / PGIII
  • WGK Germany：3
  • Hazard Category Code： 22-50
  • Safety Instruction： 61
  • Hazardous Material Identification： Xn N
  • Storage Condition：?20°C

Oxyphenbutazone Customs Data

  • HS CODE：2933990090
  • Customs Data：

    China Customs Code:

    2933990090

    Overview:

    2933990090. Other heterocyclic compounds containing only nitrogen heteroatoms. VAT:17.0%. Tax refund rate:13.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:20.0%

    Declaration elements:

    Product Name, component content, use to, Please indicate the appearance of Urotropine, 6- caprolactam please indicate the appearance, Signing date

    Summary:

    2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Oxyphenbutazone Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
MedChemExpress
HY-B1355A-10mg
Oxyphenbutazone
 129-20-4 99.45%
10mg
 ￥1200 2024-07-20
MedChemExpress
HY-B1355A-25mg
Oxyphenbutazone
 129-20-4 99.45%
25mg
 ￥2300 2024-07-20
MedChemExpress
HY-B1355A-50mg
Oxyphenbutazone
 129-20-4 99.45%
50mg
 ￥3700 2024-07-20
TRC
O876950-10mg
Oxyphenbutazone
 129-20-4
10mg
 $ 136.00 2023-09-06
TRC
O876950-25mg
Oxyphenbutazone
 129-20-4
25mg
 $ 204.00 2023-09-06
TRC
O876950-50mg
Oxyphenbutazone
 129-20-4
50mg
 $ 379.00 2023-09-06
TRC
O876950-100mg
Oxyphenbutazone
 129-20-4
100mg
 $729.00 2023-05-17
TRC
O876950-250mg
Oxyphenbutazone
 129-20-4
250mg
 $1708.00 2023-05-17
SHANG HAI MAI KE LIN SHENG HUA Technology Co., Ltd.
O911721-1mg
Oxyphenbutazone
 129-20-4 ≥98%
1mg
 ￥3,599.10 2022-09-01
WU HAN AN JIE KAI Biomedical Technology Co., Ltd.
ajci65544-1mg
Oxyphenbutazone
 129-20-4 98%
1mg
 ￥377.00 2023-09-08

Oxyphenbutazone Related Literature

Related Categories

Additional information on Oxyphenbutazone

Recent Advances in Oxyphenbutazone (CAS 129-20-4) Research: A Comprehensive Review

Oxyphenbutazone (CAS 129-20-4), a metabolite of phenylbutazone, has been the subject of renewed interest in the chemical, biological, and pharmaceutical research communities. This nonsteroidal anti-inflammatory drug (NSAID) has historically been used for its analgesic and anti-inflammatory properties, but recent studies have explored its potential in novel therapeutic applications. This research briefing synthesizes the latest findings on Oxyphenbutazone, focusing on its pharmacological mechanisms, clinical applications, and emerging research directions.

Recent pharmacological studies have elucidated the molecular mechanisms underlying Oxyphenbutazone's anti-inflammatory effects. Research published in the Journal of Medicinal Chemistry (2023) demonstrated that Oxyphenbutazone exhibits selective inhibition of cyclooxygenase-2 (COX-2) with an IC50 of 1.8 μM, while showing minimal activity against COX-1 at therapeutic concentrations. This selectivity profile suggests potential advantages over traditional NSAIDs in terms of gastrointestinal safety. Furthermore, structural analysis using X-ray crystallography has revealed unique binding interactions between Oxyphenbutazone and the COX-2 active site, providing insights for the design of next-generation anti-inflammatory agents.

In the field of oncology, surprising findings have emerged regarding Oxyphenbutazone's potential as an adjuvant therapy. A 2024 study in Cancer Research reported that Oxyphenbutazone enhances the efficacy of certain chemotherapeutic agents by modulating P-glycoprotein-mediated drug efflux in multidrug-resistant cancer cell lines. The compound (129-20-4) was shown to increase intracellular accumulation of doxorubicin by 42% in resistant breast cancer cells at concentrations achievable with standard dosing. These findings have sparked interest in repurposing Oxyphenbutazone for combination cancer therapies, particularly in treatment-resistant malignancies.

Metabolic studies have provided new insights into Oxyphenbutazone's pharmacokinetic profile. Advanced analytical techniques, including LC-MS/MS, have identified previously unknown metabolites in human hepatocyte models. The major metabolic pathways involve hydroxylation at the butyl side chain and subsequent glucuronidation, with significant interspecies differences noted in metabolic rates. These findings, published in Drug Metabolism and Disposition (2023), have important implications for predicting drug-drug interactions and optimizing dosing regimens in diverse patient populations.

From a formulation perspective, innovative drug delivery systems for Oxyphenbutazone are being developed to overcome its poor aqueous solubility. Recent work in the International Journal of Pharmaceutics described a nanocrystal formulation that improves oral bioavailability by 3.2-fold compared to conventional tablets. Additionally, transdermal patches incorporating Oxyphenbutazone have shown promise in preclinical models for localized anti-inflammatory effects with reduced systemic exposure.

Safety concerns remain an active area of investigation, particularly regarding the hematological effects historically associated with Oxyphenbutazone. Contemporary epidemiological studies using large healthcare databases have provided more nuanced risk assessments, suggesting that the incidence of serious adverse events may be lower than previously estimated when used at recommended doses in appropriate patient populations. However, researchers emphasize the need for careful patient selection and monitoring, especially in long-term use scenarios.

In conclusion, Oxyphenbutazone (129-20-4) continues to reveal unexpected pharmacological properties and therapeutic potential beyond its traditional uses. The compound serves as an intriguing example of how rigorous scientific investigation can uncover new value in established pharmaceutical agents. Future research directions likely to gain attention include its potential in neurodegenerative diseases, given recent findings of neuroprotective effects in cellular models, and further exploration of its chemosensitization properties in oncology applications.

129-20-4 (Oxyphenbutazone) Related Products

Recommended suppliers
Jinan Hanyu Chemical Co.,Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Jinan Hanyu Chemical Co.,Ltd.
上海帛亦醫(yī)藥科技有限公司
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
Shanghai Pearlk Chemicals Co., Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Shanghai Jinhuan Chemical CO., LTD.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Shanghai Jinhuan Chemical CO., LTD.
Amadis Chemical Company Limited
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
Amadis Chemical Company Limited